MedBulletinsAura Celeste
Urology

Monthly urology bulletin — November 6, 2026

🎧 Listen to this issueAudio newscast · 5:03 min

Period covered: October 7 to November 6, 2026. The month was dominated by the ESMO Congress (Madrid, October 23–27), with one positive and one negative trial in muscle-invasive bladder cancer (MIBC) and long-term survival data in metastatic prostate cancer. We include 5 verified items. We found no verifiable items from the period in stones and endourology or in andrology, transplantation, pediatric urology and robotic surgery.

Uro-oncology

1. VOLGA: perioperative durvalumab + enfortumab vedotin improves EFS and OS in cisplatin-ineligible MIBC

[Congress] [International]
Open-label phase 3 trial (NCT04960709), funded by AstraZeneca, presented at ESMO 2026 and published in NEJM: 695 patients with MIBC who were cisplatin-ineligible or declined cisplatin, randomized 1:1:1 to neoadjuvant durvalumab + enfortumab vedotin (D+EV), radical cystectomy and adjuvant durvalumab; the same regimen plus tremelimumab (D+T+EV); or radical cystectomy with or without approved adjuvant treatment. With D+EV, event-free survival improved (HR 0.51; 95% CI 0.38–0.67; P<.0001; median not reached vs 12.1 months), as did overall survival (HR 0.58; 95% CI 0.40–0.83; P=.0027; 24-month OS 78% vs 69%); centrally reviewed pathologic complete response 40% vs 8%. The triplet improved EFS (HR 0.61) but not OS (HR 0.77; P=.12) and was more toxic (treatment-related grade 3–4 adverse events in the presentation: 42% with the triplet vs 30% with D+EV; grade ≥3 in the publication: 44.5% vs 30.7%; 5 treatment-related deaths vs 1).
Why it matters: this is a perioperative regimen with an overall survival benefit in the cisplatin-ineligible population, a large group in our practice; it is an interim analysis of an AstraZeneca trial, and the FDA, which granted Priority Review, expects to act in the fourth quarter of 2026, according to the manufacturer's release. Access in the Dominican Republic will be limited by cost.

Sources

2. KEYNOTE-866: adding perioperative pembrolizumab to neoadjuvant gemcitabine–cisplatin did not significantly improve event-free survival

[Congress] [International]
Double-blind phase 3 trial presented at ESMO 2026 (abstract 4735O) and published in Annals of Oncology: 907 cisplatin-eligible MIBC patients randomized to pembrolizumab or placebo with neoadjuvant gemcitabine-cisplatin, radical cystectomy, and adjuvant pembrolizumab or placebo. EFS did not improve significantly (HR 0.88; 95% CI 0.71–1.10) and OS was similar (HR 1.00; 95% CI 0.79–1.27; not formally tested), despite a numerically higher pathologic complete response rate (44.4% vs 35.8%; not formally tested). The ENERGIZE trial (CA017-078; perioperative nivolumab + neoadjuvant gemcitabine-cisplatin), presented at the same meeting, also missed both co-primary endpoints, pathologic complete response and EFS (HR 0.94; P=.67).
Why it matters: it suggests that a higher pathologic complete response rate is not an adequate surrogate for survival; in cisplatin-eligible patients, cisplatin-based neoadjuvant chemotherapy remains the accessible standard while enfortumab vedotin–based regimens reshape the field.

Sources

3. PEACE-1 at nearly 8 years: the abiraterone benefit in de novo metastatic prostate cancer persists

[Congress] [France / Europe]
Long-term survival analysis of the phase 3 PEACE-1 trial (1,173 patients with de novo metastatic castration-sensitive prostate cancer; 2×2 factorial design testing abiraterone and prostate radiotherapy on top of ADT with or without docetaxel), presented at ESMO 2026 (abstract 2215O). At a median follow-up of 7.7 years, abiraterone improved OS in the overall population (HR 0.75; 95% CI 0.65–0.87; P=.0001) and in the ADT + docetaxel subgroup, n=710 (HR 0.68; median 6.2 vs 4.4 years; 8-year OS 40.3% vs 27.1%). The interaction by disease volume was not significant (P=.56); the estimate in low-volume disease was imprecise.
Why it matters: it supports triplet therapy (ADT + docetaxel + an androgen receptor pathway inhibitor), without the data supporting a different benefit by disease volume; generic abiraterone is one of the most affordable options in our setting.

Sources

4. CAPItello-281: descriptive overall survival analysis numerically favored capivasertib

[Congress] [International]
An updated, descriptive OS analysis of the phase 3 CAPItello-281 trial was presented at ESMO 2026 (1,012 men with PTEN-deficient metastatic hormone-sensitive prostate cancer; capivasertib + abiraterone vs placebo + abiraterone, with prednisone or prednisolone and androgen deprivation therapy in both arms), the basis of the June 12, 2026 FDA approval on radiographic PFS (median 33.2 vs 25.7 months; HR 0.81). At this ad hoc data cutoff, with 42% maturity, OS numerically favored capivasertib (HR 0.82; 95% CI 0.68–0.99; nominal P=.044; median 57.4 vs 46.5 months); as a descriptive analysis, it does not support a confirmatory conclusion. According to the presented abstract, the safety profile was consistent with the primary analysis, with no new safety signals.
Why it matters: with a PFS gain of about 7.5 months and no formally proven OS benefit yet, the toxicity-cost balance is uncertain; it also requires PTEN immunohistochemistry, which is scarce in the region.

Sources

BPH and voiding dysfunction

5. Bipolar enucleation (BipolEP) versus TURP: noninferior at 12 months, according to the authors

[Clinical trial] [Europe]
Open-label, two-center randomized noninferiority trial (Pallauf et al., European Urology Focus, October 23; registry NCT03503721, sponsored by Salzburger Landeskliniken): 84 men with prostates of 40–150 mL, IPSS ≥15 and Qmax ≤15 mL/s or retention, randomized to bipolar enucleation or TURP; 66 were included in the primary per-protocol analysis. Median 12-month IPSS was 5 points in both arms; the authors conclude that enucleation is noninferior to TURP. Enucleation removed more tissue (38.4 vs 25.0 g) with longer operative time (86 vs 67 min) and more minor early complications (Clavien 1–2: 54% vs 28%); grade ≥3 complications (10%) occurred only after TURP.
Why it matters: a small trial, with 18 of 84 participants (21%) excluded from the per-protocol analysis and short follow-up, but it suggests enucleation can be done with the bipolar equipment many Dominican hospitals already have, without a laser.

Sources

Stones and endourology

No verifiable trials or regulatory decisions dated within the period.

Andrology, transplantation, pediatric urology and robotic surgery

No verifiable trials or regulatory decisions dated within the period.

Upcoming meetings and dates

Get every issue by email

Free. One email with each new issue, with a short summary and links to the page and the audio. No ads inside the content: any sponsor is identified and has no say in the selection. We do not share your data; unsubscribe with a single message.